In a recent study, researchers have engineered a therapeutic system to target liver cancer by combining mesenchymal stem cells (MSCs) with this oncolytic adenovirus that carries a bispecific antibody to PD-L1, an immunosuppressive molecule that is frequently overexpressed in solid tumors, and this BiTE is specifically designed to bind with high affinity to PD-L1. This evidence concerns the gene CD274 and liver cancer.